[go: up one dir, main page]

MA31162B1 - Préparation pharmaceutique pour soulager l'endométriose - Google Patents

Préparation pharmaceutique pour soulager l'endométriose

Info

Publication number
MA31162B1
MA31162B1 MA32138A MA32138A MA31162B1 MA 31162 B1 MA31162 B1 MA 31162B1 MA 32138 A MA32138 A MA 32138A MA 32138 A MA32138 A MA 32138A MA 31162 B1 MA31162 B1 MA 31162B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
bone density
dilution
endometriosis
uterine lining
Prior art date
Application number
MA32138A
Other languages
Arabic (ar)
English (en)
Inventor
Christian Seitz
Annemarie Wasserfall
Holger Zimmermann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA31162B1 publication Critical patent/MA31162B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique conçue pour traiter une endométriose sans réduire la densité osseuse. Cette composition contient un gestagène anti-androgène, de préférence 17a-cyanométhyl-17-ß-hydroxyestra-4,9-dièn-3one (dienogest), acétate de cyprotérone ou acétate de chlormadinone, dans une dose journalière qui est au maximum deux fois supérieure à la dose d'inhibition d'ovulation, avec un ou plusieurs adjuvants/supports pharmaceutiquement acceptables. La composition pharmaceutique selon cette invention permet de traiter une endométriose sans influencer négativement le métabolisme osseux, ni la densité osseuse, et permet en même temps de maintenir à un niveau acceptable les effets secondaires connus (par ex. Bouffées de chaleur, acné, influence négative sur le profil lipidique) engendrés par les médicaments classiques. Ladite composition pharmaceutique est par conséquent adaptée à une application à long terme.
MA32138A 2007-03-01 2009-08-04 Préparation pharmaceutique pour soulager l'endométriose MA31162B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07004202A EP1977752A1 (fr) 2007-03-01 2007-03-01 Composition pharmaceutique destinée à réduire l'endométriose
PCT/EP2008/001451 WO2008104342A1 (fr) 2007-03-01 2008-02-23 Préparation pharmaceutique conçue pour traiter une endométriose

Publications (1)

Publication Number Publication Date
MA31162B1 true MA31162B1 (fr) 2010-02-01

Family

ID=38045772

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32138A MA31162B1 (fr) 2007-03-01 2009-08-04 Préparation pharmaceutique pour soulager l'endométriose

Country Status (18)

Country Link
EP (2) EP1977752A1 (fr)
JP (1) JP2010520159A (fr)
KR (1) KR20090119829A (fr)
CN (1) CN101583364A (fr)
AU (1) AU2008221012A1 (fr)
BR (1) BRPI0806598A2 (fr)
CA (1) CA2673936A1 (fr)
CO (1) CO6190606A2 (fr)
CR (1) CR10912A (fr)
DO (1) DOP2009000171A (fr)
EA (1) EA200900829A1 (fr)
EC (1) ECSP099482A (fr)
MA (1) MA31162B1 (fr)
MX (1) MX2009007259A (fr)
NZ (1) NZ577761A (fr)
SV (1) SV2009003324A (fr)
TN (1) TN2009000263A1 (fr)
WO (1) WO2008104342A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874806A (zh) * 2009-04-29 2010-11-03 北京本草天源药物研究院 一种地诺孕素固体制剂
CN102670519B (zh) * 2011-03-16 2014-06-11 重庆莱美药业股份有限公司 一种可快速溶出的地诺孕素口服制剂及其制备方法
CN103304619B (zh) * 2013-06-08 2015-12-02 西藏海思科药业集团股份有限公司 一种地诺孕素化合物
WO2025124422A1 (fr) * 2023-12-13 2025-06-19 长春金赛药业有限责任公司 Composition de modulation d'hormone femelle implantable sous-cutanée in situ, son procédé de préparation et son utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP1535618A1 (fr) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Préparation pharmaceutique pour le traitement hormonal continuel sur plus de 21-28 jours comprenant deux compositions d'estrogène et/ou de progestine
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
EP1655031A1 (fr) * 2004-10-08 2006-05-10 Schering AG Utilisation de dienogest pour contraceptives hormonelles avec cycle prolongué

Also Published As

Publication number Publication date
EP2059248A1 (fr) 2009-05-20
JP2010520159A (ja) 2010-06-10
DOP2009000171A (es) 2009-08-31
CN101583364A (zh) 2009-11-18
NZ577761A (en) 2012-03-30
ECSP099482A (es) 2009-08-28
EP1977752A1 (fr) 2008-10-08
EA200900829A1 (ru) 2010-02-26
CA2673936A1 (fr) 2008-09-04
WO2008104342A1 (fr) 2008-09-04
CO6190606A2 (es) 2010-08-19
AU2008221012A1 (en) 2008-09-04
SV2009003324A (es) 2009-10-02
CR10912A (es) 2009-08-13
BRPI0806598A2 (pt) 2014-05-06
TN2009000263A1 (en) 2010-10-18
MX2009007259A (es) 2009-07-10
KR20090119829A (ko) 2009-11-20

Similar Documents

Publication Publication Date Title
Narang et al. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier
Zelander Ultrastructure of the mouse adrenal cortex: an electron microscopical study in intact and hydrocortisone-treated male adults
Selzner et al. Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism
BladÉ et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant
Zou et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice
Tipoe et al. Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice
Filliol et al. RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis
Ikeuchi et al. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: a case report
MA31162B1 (fr) Préparation pharmaceutique pour soulager l'endométriose
Merkulova et al. Ponatinib treatment promotes arterial thrombosis and hyperactive platelets
EP3530288A3 (fr) Procédés pour le traitement d'états pathologiques liés à l'activation du complément masp-2 dépendant
EP3276004A3 (fr) Procédés de traitement d'une maladie rénale chronique
Kim et al. Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma
Loughlin Calcium channel blockers and prostate cancer
Zhang et al. A new approach for Alzheimer's disease treatment through P-gp regulation via ibuprofen
Gomez-Lechon et al. The immunosuppressant drug FK506 prevents Fas-induced apoptosis in human hepatocytes
Gardini et al. Agmatine inhibits the proliferation of rat hepatoma cells by modulation of polyamine metabolism
Jensen et al. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
Kim et al. Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines
Butty et al. Chronic lymphocytic leukemia–associated membranous glomerulopathy: Remission with fludarabine
Root et al. Burkitt’s lymphoma of the testicle: report of 2 cases occurring in elderly patients
Zhao et al. Lipopolysaccharide protects against acetaminophen-induced hepatotoxicity by reducing oxidative stress via the TNF-α/TNFR1 pathway
Mathurin et al. Treatment of severe forms of alcoholic hepatitis: where are we going?
Ceresa et al. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells
Engblom et al. Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis